Cellulose sulfate - Polydex Pharmaceuticals/CONRAD

Drug Profile

Cellulose sulfate - Polydex Pharmaceuticals/CONRAD

Alternative Names: Ushercell

Latest Information Update: 03 Feb 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer CONRAD
  • Class Antivirals; Biopolymers; Contraceptives; Glucans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bacterial vaginosis; Pregnancy
  • Discontinued Chlamydial infections; Gonorrhoea; HIV infections

Most Recent Events

  • 31 Jul 2012 Cellulose sulfate - Polydex Pharmaceuticals/CONRAD is available for licensing as of 31 Jul 2012. http://www.polydex.com/
  • 31 Dec 2010 Suspended - Clinical-Phase-Unknown for Pregnancy (Prevention) in Zimbabwe (Vaginal)
  • 31 Dec 2010 Suspended - Phase-I for Pregnancy (Prevention) in Dominican Republic (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top